Failure of buparvaquone (Butalex) in the treatment of canine visceral leishmaniosis.
作者信息
Vexenat J A, Croft S L, Furtado Campos J H, Miles M A
机构信息
Medical Parasitology Laboratory, University of Brasilia, Brasilia DF, Brazil.
出版信息
Vet Parasitol. 1998 May;77(1):71-3. doi: 10.1016/s0304-4017(96)01150-8.
PMID:9652385
Abstract
Buparvaquone (Butalex), a therapeutic for theileriosis, has been shown to have anti-leishmanial activity in vitro. Seven dogs with symptomatic, parasitologically positive, canine visceral leishmaniosis were treated with Butalex at 5 mg kg(-1) body weight using four doses over 12 days. Two animals showed minor clinical improvement (growth of healthy hair) but all remained parasitologically positive and disease progression was not halted.
摘要
Zotero 插件